BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY; International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J Thorac Oncol 2020;15:176-89. [PMID: 31712134 DOI: 10.1016/j.jtho.2019.10.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Boisselier P, Coutte A, Martin E, Pointreau Y. [Stereotactic radiotherapy for localized primary lung tumours of stage T1-T2]. Cancer Radiother 2022;26:755-9. [PMID: 36075829 DOI: 10.1016/j.canrad.2022.07.005] [Reference Citation Analysis]
2 Gulstene S, Ruwanpura T, Palma D, Joseph N. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer – A Done Deal? Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Manafi-Farid R, Askari E, Shiri I, Pirich C, Asadi M, Khateri M, Zaidi H, Beheshti M. [18F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: Technical aspects and potential clinical applications. Semin Nucl Med 2022:S0001-2998(22)00035-6. [PMID: 35717201 DOI: 10.1053/j.semnuclmed.2022.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kong Y, Xu H, Huang Y, Wei Z, Ye X. Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer. Asia Pac J Clin Oncol 2022. [PMID: 35599449 DOI: 10.1111/ajco.13766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang Z, Nie Z, Chen Q, Du C, Luo D, Liu L, Guo S, Li J, Sun R, Liu S, Lu Z, Yuan L, Lu Z, Mai H, Tang L. Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission. Oral Oncology 2022;128:105851. [DOI: 10.1016/j.oraloncology.2022.105851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol 2022;61:403-8. [PMID: 34913815 DOI: 10.1080/0284186X.2021.2012253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Murphy MC, Wrobel MM, Fisher DA, Cahalane AM, Fintelmann FJ. Update on Image-Guided Thermal Lung Ablation: Society Guidelines, Therapeutic Alternatives, and Postablation Imaging Findings. AJR Am J Roentgenol 2022. [PMID: 35319908 DOI: 10.2214/AJR.21.27099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brooks ED, Wang X, De B, Verma V, Williamson TD, Hunter R, Mohamed ASR, Ning MS, Zhang X, Chang JY. An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone". Radiat Oncol 2022;17:4. [PMID: 34991637 DOI: 10.1186/s13014-021-01977-1] [Reference Citation Analysis]
9 Matsuo Y, Hanazawa H, Kishi N, Ueki K, Mizowaki T. Radiation Therapy for Intrathoracic Recurrence of Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_328] [Reference Citation Analysis]
10 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ghosn M, Solomon SB. Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy. Cancers (Basel) 2021;13:5202. [PMID: 34680348 DOI: 10.3390/cancers13205202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA; STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 2021;22:1448-57. [PMID: 34529930 DOI: 10.1016/S1470-2045(21)00401-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 46.0] [Reference Citation Analysis]
13 Hu S, Luo M, Li Y. Machine Learning for the Prediction of Lymph Nodes Micrometastasis in Patients with Non-Small Cell Lung Cancer: A Comparative Analysis of Two Practical Prediction Models for Gross Target Volume Delineation. Cancer Manag Res 2021;13:4811-20. [PMID: 34168500 DOI: 10.2147/CMAR.S313941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Palussière J, Cazayus M, Cousin S, Cabart M, Chomy F, Catena V, Buy X. Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence? Curr Oncol Rep 2021;23:81. [PMID: 33948744 DOI: 10.1007/s11912-021-01072-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Finazzi T, Schneiders FL, Senan S. Developments in radiation techniques for thoracic malignancies. Eur Respir Rev 2021;30:200224. [PMID: 33952599 DOI: 10.1183/16000617.0224-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Stirling RG, Chau C, Shareh A, Zalcberg J, Fischer BM. Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology 2021;16:784-97. [DOI: 10.1016/j.jtho.2021.01.1622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Demmy TL. Commentary: Troubleshooting Redo VATS. Semin Thorac Cardiovasc Surg 2021;33:238-9. [PMID: 33181299 DOI: 10.1053/j.semtcvs.2020.10.025] [Reference Citation Analysis]
18 Lopes AR, Russo A, Li AY, McCusker MG, Kroopnick JM, Scilla K, Mehra R, Rolfo C. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report. Transl Lung Cancer Res 2020;9:2149-56. [PMID: 33209634 DOI: 10.21037/tlcr-20-408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Moore S, Leung B, Wu J, Ho C. Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC. JTO Clin Res Rep 2020;1:100083. [PMID: 34589962 DOI: 10.1016/j.jtocrr.2020.100083] [Reference Citation Analysis]
20 Friedes C, Mai N, Fu W, Hu C, Han P, Marrone KA, Voong KR, Hales RK. Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy. Lung Cancer 2020;145:119-25. [PMID: 32434118 DOI: 10.1016/j.lungcan.2020.04.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Aoki S, Yamashita H, Takahashi W, Nawa K, Ota T, Imae T, Ozaki S, Nozawa Y, Nakajima J, Sato M, Anraku M, Nitadori J, Karasaki T, Abe O, Nakagawa K. Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients. Oncol Lett 2020;19:2695-704. [PMID: 32218820 DOI: 10.3892/ol.2020.11407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Robinson DG, Snow S, Brade A, Ho C, Wheatley-price P, Blais N, Cheema P, Swaminath A. Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations. Cancer Treatment and Research Communications 2020;25:100265. [DOI: 10.1016/j.ctarc.2020.100265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]